Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -239.78% is 84% above its 5-year average of -1545.10%, near the high end of its 5-year range (-21188.71%–27.80%).
68.16% above its 12-month average of -753.11%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2025 (2025-12-31): -81.76%.
EBITDA MARGIN
-239.78%
EBITDA MARGIN AVG TTM
-753.11%
EBITDA MARGIN AVG 3Y
-724.50%
EBITDA MARGIN AVG 5Y
-1545.10%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+68.16%
CURRENT VS 3Y AVG
+66.90%
CURRENT VS 5Y AVG
+84.48%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Korsana Biosciences, Inc.
Market Cap
$143.81M
EBITDA Margin
-239.78%
TTM Avg
-753.11%
3Y Avg
-724.50%
5Y Avg
-1545.10%
Market Cap
$143.10M
EBITDA Margin
-783.01%
TTM Avg
-1033.45%
3Y Avg
-1010.27%
5Y Avg
-3715.70%
Market Cap
$143.21M
EBITDA Margin
-16238.30%
TTM Avg
-8929.91%
3Y Avg
-4730.54%
5Y Avg
-4730.54%
Market Cap
$148.31M
EBITDA Margin
-0.19%
TTM Avg
-1.66%
3Y Avg
-11.02%
5Y Avg
-42.72%
Market Cap
$146.98M
EBITDA Margin
-550.97%
TTM Avg
-275.49%
3Y Avg
-275.49%
5Y Avg
-275.49%
Market Cap
$139.73M
EBITDA Margin
-103.63%
TTM Avg
-143.63%
3Y Avg
-176.25%
5Y Avg
-194.05%
Market Cap
$148.36M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$139.42M
EBITDA Margin
-221.15%
TTM Avg
-221.15%
3Y Avg
-221.15%
5Y Avg
-221.15%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Korsana Biosciences, Inc. (KRSA) | $143.81M | -239.78% | -753.11% | -724.50% | -1545.10% |
| Nyxoah S.A. (NYXH)vs › | $143.10M | -783.01% | -1033.45% | -1010.27% | -3715.70% |
| Immuneering Corporation (IMRX)vs › | $143.21M | -16238.30% | -8929.91% | -4730.54% | -4730.54% |
| LifeMD, Inc. (LFMDP)vs › | $148.31M | -0.19% | -1.66% | -11.02% | -42.72% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.98M | -550.97% | -275.49% | -275.49% | -275.49% |
| Fortress Biotech, Inc. (FBIOP)vs › | $139.73M | -103.63% | -143.63% | -176.25% | -194.05% |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $148.36M | N/A | N/A | N/A | N/A |
| Alpha Cognition Inc (ACOG)vs › | $139.42M | -221.15% | -221.15% | -221.15% | -221.15% |
| Anavex Life Sciences Corp. (AVXL)vs › | $149.20M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $150.59M | -47.00% | -68.63% | -61.93% | -48.63% |
Gross Margin
100.0%
EBITDA Margin
-239.8%
Operating Margin
-239.8%
Net Margin
-353.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | -81.76% |
| 2025-09-30 | -114.97% |
| 2025-06-30 | -1797.85% |
| 2025-03-31 | -1798.77% |
| 2024-12-31 | 27.80% |
| 2024-09-30 | -581.44% |
| 2022-06-30 | -4384.31% |
| 2022-03-31 | -1819.41% |
| 2021-12-31 | -2681.05% |
| 2021-09-30 | -3229.02% |
| 2021-06-30 | -535.27% |
| 2021-03-31 | -21188.71% |
| 2020-12-31 | -14100.75% |
| 2020-09-30 | -5298.00% |
| 2020-06-30 | -2544.59% |
| 2020-03-31 | -1968.74% |
| 2019-12-31 | -1751.05% |
| 2019-09-30 | -1954.15% |
| 2019-06-30 | -1979.67% |
